Quarterly report pursuant to Section 13 or 15(d)

Common Stock

v3.2.0.727
Common Stock
6 Months Ended
Jun. 30, 2015
Equity [Abstract]  
Common Stock
Common Stock
Authorized, Issued, and Outstanding Common Shares
The Company’s common stock has a par value of $0.001 per share and consists of 125,000,000 authorized shares as of June 30, 2015, and December 31, 2014; 13,903,832 and 8,512,103 shares were issued and outstanding at June 30, 2015, and December 31, 2014, respectively. The following table summarizes common stock share activity for the six months ended June 30, 2015: 
 
Shares of
Common Stock
Balance, December 31, 2014
8,512,103

Common stock issued through April 2015 Offering
5,376,622

Common stock issued through employee stock purchase plan
15,107

Balance, June 30, 2015
13,903,832


Shares Reserved for Future Issuance
The Company had reserved shares of common stock for future issuance as follows:
 
 
As of
 
As of
 
June 30,
2015
 
December 31,
2014
Outstanding stock options
1,153,369

 
615,322

Outstanding Series C-1 Preferred warrants
14,033

 
14,033

For possible future issuance under 2014 Equity Incentive Plan (Note 8)
618,773

 
180,610

For possible future issuance under Employee Stock Purchase Plan (Note 8)
52,050

 
37,746

For possible future issuance under 2015 Inducement Plan (Note 8)
325,000

 

Total common shares reserved for future issuance
2,163,225

 
847,711

Common Stock Warrants
The Company had outstanding common stock warrants issued in connection with the Note and Warrant Purchase Agreements (see Note 4) and in connection with certain convertible preferred stock agreements (see Note 6).
The December 2011 Note and Warrant Purchase Agreement included warrants to purchase 26,000 shares of the Company’s common stock at $0.20 per share. The warrants could be exercised for shares of common stock, in accordance with their terms. The number of shares of common stock that could be purchased by exercising the warrants would vary based on the event that occurred and would be calculated in accordance with the December 2011 Note and Warrant Purchase Agreements (see Note 4).
On December 11, 2013, holders of the June 2013 Notes exercised their rights under the June 2013 Note and Warrant Agreement to receive warrants to purchase shares of the Company’s common stock. As a result of this exercise, the Company issued warrants to purchase 88,987 shares of the Company’s common stock to the holders of the June 2013 Notes at an exercise price of $0.20 per share. These warrants were exercisable until June 28, 2018, and were exercised in connection with the IPO.
On December 11, 2013, in connection with the Series D-2 Convertible Preferred Stock offering, the Company issued warrants to purchase 87,532 shares of the Company’s common stock at an exercise price of $0.20 per share. These warrants were exercisable until December 11, 2018, and were exercised in connection with the IPO. In addition, as a result of the conversion of the principal and interest outstanding on the 2011-2012 Notes into Series D-1 Preferred and Series D-2 Preferred (see Note 4), in accordance with the amended terms of the agreement, the number of common shares underlying the warrants issued in connection with the 2011-2012 Notes was increased by 54,120 to a total of 80,120.
In connection with the consummation of the IPO in May 2014, the outstanding common stock warrants were exercised at an exercise price of $0.20 per share and the holders received 275,687 shares of common stock.
All previously described warrants met the definition of a derivative financial instrument and were accounted for as derivatives. The warrants were stated at fair value at each reporting period end date prior to being exercised in May 2014 in conjunction with the Company’s IPO. The combined fair value of the common stock warrant derivative liabilities, including warrants issued with the sale of Series D-2 Preferred, was $12,200 as of December 31, 2013, and then decreased to $9,998 as of March 31, 2014. The combined fair value of the common stock warrant derivative liabilities continued to decrease in the second quarter of 2014 to $2,701 as of May 2, 2014, and this amount was settled to additional paid in capital on that date as the warrants were exercised in conjunction with the Company's IPO. The fair value adjustment of the long-term derivative liability was recorded as other income in the amounts of $0 for both the three and six months ended June 30, 2015, respectively, and $7,297 and $10,405 for the three and six months ended June 30, 2014, respectively.